Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$73.17 USD

73.17
8,786,290

-0.09 (-0.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific (BSX) Misses on Q1 Earnings, Updates View

Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.

    Boston Scientific (BSX): Beats on Q1 Sales, Misses Earnings

    Boston Scientific's adjusted earnings of 29 cents per share missed the Zacks Consensus Estimate in the first quarter.

      Will Boston Scientific (BSX) Surprise this Earnings Season?

      Boston Scientific Corporation (BSX) is scheduled to report first-quarter 2017 results before the opening bell on Apr 27.

        Boston Scientific's Emerging Markets Grow Amid Currency Woes

        On Apr 11 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

          Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA

          Boston Scientific Corporation (BSX) recently signed a definitive agreement to acquire Switzerland-based Symetis SA for $435 million in up-front cash, in a bid to fortify its structural heart business in Europe.

            Madeleine Johnson headshot

            Obamacare Repeal Vote Looms: What Investors Need to Know

            Investors' eyes will be focused on Congress today, as the House is scheduled to vote on the American Healthcare Act (AHCA). Whether you think it???s "Obamacare Lite" or "dead on arrival" like Sen. Rand Paul, the AHCA has certainly made an impact on Wall Street, as well as the entire healthcare industry since its announcement.

              Madeleine Johnson headshot

              Your Guide to the Stock Winners & Losers of Trump's Obamacare Replacement Bill

              Whether you think it???s "Obamacare Lite," "Obamacare 2.0," "dead on arrival" like Rand Paul, or you actually like the bill, the American Healthcare Act (AHCA) has certainly made an impact on the entire healthcare industry since its announcement. Who are the stock winners and losers so far? And who will be affected if it's passed?

                Swarup Gupta headshot

                4 Big Winners of Trump's Healthcare Plan

                The new healthcare legislation has its own sets of winners and losers.

                  Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View

                  Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.

                    Boston Scientific (BSX) Beats on Earnings & Revenues in Q4

                    Boston Scientific (BSX) has posted positive results with both its top line and bottom line beating the Zacks Consensus Estimate.

                      Tracey Ryniec headshot

                      5 Stocks with Spectacular Earnings Charts

                      These 5 companies have perfect earnings beat records for the last 5 years.

                        Medical Product Earnings Due on Feb 2: BDX, BSX, IDXX, ATHN

                        The medical sector is likely to see 2.9% earnings growth on 5.7% higher revenues in the quarter.

                          Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?

                          Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2.

                            Boston Scientific Down on Risks; Innovations Raise Hope

                            On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

                              Boston Scientific Acquires Neovasc to Boost Heart Business

                              Boston Scientific Corporation (BSX) recently completed the acquisition of specialty medical device company Neovasc Inc.'s (NVCN) tissue processing technology.

                                Boston Scientific (BSX) Inks $75 Million Deal with Neovasc

                                Boston Scientific Corporation (BSX) recently inked a deal with specialty medical device company Neovasc Inc.